Literature DB >> 21911284

Performance of three point-of-care urinalysis test devices for drugs of abuse and therapeutic drugs applied in the emergency department.

Milly E Attema-de Jonge1, Suzanne Y G Peeters, Eric J F Franssen.   

Abstract

BACKGROUND: Point-of-care tests for toxicological screening of patients for drugs of abuse and therapeutic drugs may be helpful in the emergency department (ED) to assist in a rapid diagnosis.
OBJECTIVES: In this prospective study, the performance of TesTcard9® (Varian; Middelburg, Netherlands), Syva RapidTest d.a.u. 10® (Dade Behring; Leusden, Netherlands), and Triage TOX Drug Screen® (Biosite; Bunnik, Netherlands), when applied on-site in the ED by physicians and nurses, was evaluated.
METHODS: Patients in the ED were included in the study when a physician thought the patient could benefit from a toxicological screen. Urine samples were screened utilizing the three point-of-care tests. All three tests simultaneously determined the presence of amphetamines, methamphetamine, opiates, methadone (except for TesTcard9), cocaine, cannabis, barbiturates, benzodiazepines, tricyclic antidepressants, and phencyclidine. The same urine specimen was analyzed in the pharmacy department using Syva EMIT II immunoassay and chromatographic confirmation. The results were compared for agreement.
RESULTS: During the 6-month study period, 80 urine samples were screened. In total, 62 (78%) specimens were found positive for at least one drug. Amphetamines (n = 16), cocaine (n = 27), cannabis (n = 25), benzodiazepines (n = 25), and opiates (n = 8) were the most frequently found. The sensitivity and specificity of all three devices were higher than 93% for these compounds, with the exception of the sensitivity for cannabis with the TesTcard9 (88%) and the sensitivity for benzodiazepines with the Syva RapidTest d.a.u. 10 (88%) and TesTcard9 (80%).
CONCLUSION: In the ED setting, the Triage TOX Drug Screen performed better than the other point-of-care tests, probably due to its more objective reading system and its adequate quality controls.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911284     DOI: 10.1016/j.jemermed.2011.01.031

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  9 in total

1.  Fast, Sensitive, and Quantitative Point-of-Care Platform for the Assessment of Drugs of Abuse in Urine, Serum, and Whole Blood.

Authors:  Ying Li; Uvaraj Uddayasankar; Bangshun He; Ping Wang; Lidong Qin
Journal:  Anal Chem       Date:  2017-07-26       Impact factor: 6.986

2.  Detection and quantification of tricyclic antidepressants and other psychoactive drugs in urine by HPLC/MS/MS for pain management compliance testing.

Authors:  Justin L Poklis; Carl E Wolf; Ashley Goldstein; M Lauren Wolfe; Alphonse Poklis
Journal:  J Clin Lab Anal       Date:  2012-07       Impact factor: 2.352

3.  Competitive volumetric bar-chart chip with real-time internal control for point-of-care diagnostics.

Authors:  Ying Li; Jie Xuan; Tom Xia; Xin Han; Yujun Song; Zheng Cao; Xin Jiang; Yi Guo; Ping Wang; Lidong Qin
Journal:  Anal Chem       Date:  2015-03-18       Impact factor: 6.986

4.  Rapid detection and quantitation of drugs-of-abuse by wooden-tip electrospray ionization mass spectrometry.

Authors:  Tsz-Tsun Ng; Pui-Kin So; Bin Hu; Zhong-Ping Yao
Journal:  J Food Drug Anal       Date:  2018-10-01       Impact factor: 6.157

5.  Evaluation of the Triage TOX Drug Screen Assay for Detection of 11 Drugs of Abuse and Therapeutic Drugs.

Authors:  Hae In Bang; Mi Ae Jang; Yong Wha Lee
Journal:  Ann Lab Med       Date:  2017-11       Impact factor: 3.464

6.  Toxicological screening in the Amsterdam acute setting becomes more relevant if the standard panel of the drugs-of-abuse point-of-care test is expanded with GHB and ketamine.

Authors:  J A J van der Schaar; M E Attema-de Jonge; F M J Gresnigt; E J F Franssen
Journal:  Toxicol Rep       Date:  2020-04-20

7.  Development of a high-throughput differential mobility separation-tandem mass spectrometry (DMS-MS/MS) method for clinical urine drug testing.

Authors:  Shirin Hooshfar; Simone Tchu; Cassandra Yun; Kara L Lynch
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2022-01-03

8.  Concept of a point of care test to detect new oral anticoagulants in urine samples.

Authors:  Job Harenberg; Sandra Krämer; Shanshan Du; Christel Weiss; Roland Krämer
Journal:  Thromb J       Date:  2013-08-01

9.  Clinical value of drugs of abuse point of care testing in an emergency department setting.

Authors:  P S Lager; M E Attema-de Jonge; M P Gorzeman; L E Kerkvliet; E J F Franssen
Journal:  Toxicol Rep       Date:  2017-12-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.